Early Recurrence Adenoid Cystic Carcinoma of Paranasal Sinus, A Case Report

Nikrial Dewin Marzaini, MD, Handoko Nugroho Yossarsongko, Farilaila Rayhani, Dewi Syafriyetti Soeis

Abstract


Introduction: Adenoid cystic carcinoma (ACC) of the head and neck is a rare salivary gland tumor. It grows and spreads in silence until causing a symptom. Surgery is still the main treatment of choice although complete resection is hard to achieve most of the time.

 

Case Presentation: This report presents an adult female with ACC of the left hard palate and left maxillary sinus, this patient also had slight lymph nodes enlargement. She underwent sub-total maxillectomy followed by locoregional radiotherapy. The tumor spreads out to vertebral bones within one year and keeps on progressing despite bone radiation. It recurred locally and appeared in the neck lymph node 2 months after bone metastasis. Lung metastasis happened 3 months later and soon she passed away. Mortality happened in less than two years after initial treatment.

 

Conclusion: : High tumor grade, advanced T stage, lymph node involvement, perineural invasion, and paranasal sinus location clearly define poor prognostic factors. In this case, adjuvant radiotherapy for poor prognostic factors ACC doesn’t give any benefit in locoregional control or overall survival.

 

 


Keywords


adenoid cystic carcinoma, metastasis, paranasal sinuses, radiotherapy, recurrence

Full Text: View | Download

DOI: 10.33371/ijoc.v18i1.1081

Article Metrics

Abstract View: 341,
PDF Download: 175
             

References


Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck--An update. Oral Oncol. 2015 Jul;51(7):652-61.

Jang S, Patel PN, Kimple RJ, McCulloch TM. Clinical Outcomes and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck. Anticancer Res. 2017 Jun;37(6):3045-3052.

Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE. Adenoid cystic carcinoma of the head and neck--a 20 years experience. Int J Oral Maxillofac Surg. 2004 Jan;33(1):25-31.

Guazzo E, Bowman J, Porceddu S, et al. Advanced adenoid cystic carcinoma of the skull base - The role of surgery. Oral Oncol. 2019 Dec;99:104466.

Shen C, Xu T, Huang C, Hu C, He S. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol. 2012 May;48(5):445-9.

Jensen AD, Poulakis M, Nikoghosyan AV, et al. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiother Oncol. 2015 Feb;114(2):182-8.

Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001 Jun 20;96(3):149-58.

Vikram B, Strong EW, Shah JP, Spiro RH. Radiation therapy in adenoid-cystic carcinoma. Int J Radiat Oncol Biol Phys. 1984 Feb;10(2):221-3.

Ishida E, Ogawa T, Rokugo M, et al. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med. 2020 Jul 2;16(1):14.

Atallah S, Marc M, Schernberg A, et al. Beyond Surgical Treatment in Adenoid Cystic Carcinoma of the Head and Neck: A Literature Review. Cancer Manag Res. 2022 Jun 4;14:1879-1890.

Hitre E, Budai B, Takácsi-Nagy Z, et al. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer. 2013 Sep 3;109(5):1117-22.

Jaso J, Malhotra R. Adenoid cystic carcinoma. Archives of Pathology & Laboratory Medicine. 2011 Apr;135[4]:511-5.

Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol. 2007 Nov;31(11):1683-94.

Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992 Dec;164(6):623-8.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.